Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 4/20 | 0.47 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.47 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | PNMT | P11086 | 9/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL30615657 | 1.00 | CA1 (0.48) | CA1CA2CA12CA7CA14 | |
| SCHEMBL419457 | 0.98 | CA1 (0.50) | CA1CA2CA12CA7CA14 | |
| SCHEMBL615229 | 0.98 | CA1 (0.50) | CA1CA2CA12CA7CA14 | |
| SCHEMBL419456 | 0.98 | CA1 (0.50) | CA1CA2CA12CA7CA14 | |
| Hydrochloric Acid SCHEMBL22092770 | 0.96 | CA1 (0.52) | CA1CA2CA12CA7CA14 | |
| Hydrochloric Acid SCHEMBL30986203 | 0.96 | CA1 (0.52) | CA1CA2CA12CA7CA14 | |
| Hydrochloric Acid SCHEMBL5758866 | 0.96 | CA1 (0.52) | CA1CA2CA12CA7CA14 | |
| SCHEMBL354978 | 0.82 | OPRK1 (0.62) | — | |
| SCHEMBL3020673 | 0.82 | OPRK1 (0.62) | — | |
| SCHEMBL415207 | 0.82 | DRD2 (0.62) | PNMTKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431664-A | Curable antibacterial material, preparation method thereof, antibacterial ink and application | 广东鸿旺达新材料有限公司 | 2025-02-14 | — | — | CN | claimed |
| EP-4642455-A1 | METHOD OF TREATING TAUOPATHIES | GT Gain Therapeutics SA (CH) | 2025-11-05 | — | — | EP | disclosed |
| CN-119431664-A | Curable antibacterial material, preparation method thereof, antibacterial ink and application | 广东鸿旺达新材料有限公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2024141998-A1 | METHOD OF TREATING TAUOPATHIES | GT GAIN THERAPEUTICS SA (CH) | 2024-07-04 | — | — | WO | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| CN-111868037-B | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2023-10-13 | — | — | CN | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-20210363152-A1 | AMINOAZINE AMIDES | HOFFMANN LA ROCHE (US) | 2021-11-25 | — | — | US | disclosed |
| CN-113412113-A | Aminooxazine amides | 豪夫迈·罗氏有限公司 | 2021-09-17 | — | — | CN | disclosed |
| EP-3873473-A1 | AMINOAZINE AMIDES | F. Hoffmann-La Roche AG (CH) | 2021-09-08 | — | — | EP | disclosed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006040177-A1 | 6-AMINO(AZA)INDANE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECPTOR | ABBOTT GMBH & CO.KG (DE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006015828-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
| EP-1259484-B1 | CARBOXAMIDES USEFUL AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND OF APOLIPOPROTEIN B SECRETION | NOVARTIS AG (CH) | 2005-05-18 | — | — | EP | disclosed |
| US-6878707-B2 | Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion | NOVARTIS AG (CH) | 2005-04-12 | — | — | US | disclosed |
| US-20030109700-A1 | Carboxamides useful as inhinitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion | NOVARTIS AG (CH) | 2003-06-12 | — | — | US | disclosed |
| EP-1259484-A1 | CARBOXAMIDES USEFUL AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND OF APOLIPOPROTEIN B SECRETION | Novartis AG (CH) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001053260-A1 | CARBOXAMIDES USEFUL AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND OF APOLIPOPROTEIN B SECRETION | NOVARTIS AG (CH) | 2001-07-26 | — | — | WO | disclosed |
| US-6197798-B1 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN | NOVARTIS AG (CH) | 2001-03-06 | — | — | US | disclosed |
| WO-2001005767-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109700-A1 | Carboxamides useful as inhinitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion | APOB, CETP, MTTP | ADRA2A 500/4885ADRA2B 493/4885ADRA2C 683/4885 |
| US-20210363152-A1 | AMINOAZINE AMIDES | SLC6A15, SLC1A5, SLC7A5 | ADRA2A 570/4885ADRA2B 553/4885ADRA2C 312/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | ADRA2A 1171/4885ADRA2B 1536/4885ADRA2C 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.